Tekmira (TKMR) TKM-Ebola Gets FDA Fast Track Designation, China New Borun (BORN) Solid Results

http://pennyomega.com/img/penny_omega.jpg

chartstockalert

http://pennyomega.com/img/tkmr.jpg Tekmira Pharmaceuticals Corporation (TKMR)

Ebola disease—also called Ebola hemorrhagic fever or Ebola fever— is a severe acute viral illness often characterized by the sudden onset of fever, intense weakness, muscle pain, headache and sore throat. This is followed by vomiting, diarrhoea, rash, impaired kidney and liver function, and in some cases, both internal and external bleeding.

Ebola is introduced into the human population through close contact with the blood, secretions, organs or other bodily fluids of infected animals. Later Ebola spreads in the community through human-to-human transmission, resulting from close contact with the blood, secretions, organs or other bodily fluids of infected people.

The Ebola virus can cause severe viral haemorrhagic fever outbreaks in humans with a case fatality rate of up to 90%. Ebola haemorrhagic fever outbreaks occur primarily in remote villages in Central and West Africa, near tropical rainforests

TKMR reported that the U.S. FDA has granted Fast Track designation for the development of the company's TKM-Ebola, an anti-Ebola viral therapeutic.

Speeding the development and availability of drugs that treat serious diseases are in everyone's interest, especially when the drugs are the first available treatment or have advantages over existing treatments. The U.S. FDA has developed three distinct and successful approaches to making such drugs available as rapidly as possible: Priority Review, Accelerated Approval, and Fast Track.

Fast track is a process designed to facilitate the development, and expedite the review of drugs to treat serious conditions and fill an unmet medical need. The purpose is to get important new drugs to the patient earlier. Fast Track addresses a broad range of serious conditions.

Once a drug receives Fast Track designation, early and frequent communication between the FDA and a drug company is encouraged throughout the entire drug development and review process. The frequency of communication assures that questions and issues are resolved quickly, often leading to earlier drug approval and access by patients.

TKMR's TKM-Ebola, an anti-Ebola virus RNAi therapeutic, is being developed under a $140 million contract with the U.S. Department of Defense's Medical Countermeasure Systems BioDefense Therapeutics (MCS-BDTX) Joint Product Management Office.

http://pennyomega.com/img/tkmr_chart.png

TKMR is a biopharmaceutical company focused on advancing novel RNAi therapeutics and providing its leading lipid nanoparticle delivery technology to pharmaceutical partners. RNAi is a naturally occurring process that takes place inside cells, and includes processes whereby RNA molecules can profoundly suppress the production of specific proteins.

More about Tekmira Pharmaceuticals Corporation (TKMR) at www.tekmirapharm.com

**

http://pennyomega.com/img/crwe_logo.jpg Crown Equity Holdings Inc. (CRWE)

CRWE is currently developing its CRWE Network (CRWE-PR.com), a social networking service compatible with both, the mobile and desktop web platform, that is designed to target all the communities in the U.S. and Canada, which business model is based on selling advertising to local businesses.

A social networking service is a platform to build social networks or social relations among people who, for example, share interests, activities, backgrounds or real-life connections. Social networking services are on the rise globally.

CRWE presently has more than 80 U.S. cities, 9 cities from Canada and is currently adding 100 new sites throughout California.

crwe_connection_network



CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet

More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com

**

http://pennyomega.com/img/born.jpg China New Borun Corporation (BORN)

Keep a close eye on BORN. The company reported strong performance on its unaudited financial results, with total revenues exceeding the high-end of guidance and profitability expanding to a 12-month high.

For the fourth quarter 2013, BORN posted total revenue of RMB657.8 million ($107.9 million) , a 30.7% increase year over year, gross profit of RMB78.6 million ($12.9 million), increased by 44.3% compared to the same period the prior year, and net income of RMB30.5 million ($5.0 million), a 41.1% increase compared to the fourth quarter of 2012.

According to its financial outlook, BORN expects that its revenue for the first quarter of 2014 will be in the range of RMB500 million ($82.0 million) to RMB530 million ($86.9 million), an increase of approximately 11% to 18% over the same quarter of 2013.

http://pennyomega.com/img/born_chart.png

BORN is a leading producer and distributor of corn-based edible alcohol sold as an ingredient to producers of baijiu, a popular grain-based alcoholic beverage in China. BORN also produces DDGS Feed, liquid carbon dioxide and crude corn oil as by-products of edible alcohol production, and CPE and foam insulation that are widely used in chemical industries.

More about China New Borun Corporation (BORN) at www.chinanewborun.com

**

Read Full Disclaimer at www.pennyomega.com/disclaimer

6.3.14 09:40

Werbung


bisher 0 Kommentar(e)     TrackBack-URL

Name:
Email:
Website:
E-Mail bei weiteren Kommentaren
Informationen speichern (Cookie)

Die Datenschuterklärung und die AGB habe ich gelesen, verstanden und akzeptiere sie. (Pflicht Angabe)


 Smileys einfügen